These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21528276)

  • 1. Epidermal growth factor-DNA conjugate for two-step targeting.
    Gedda L; Carlsson J
    Int J Oncol; 1997 Oct; 11(4):789-95. PubMed ID: 21528276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
    Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
    Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy.
    Gedda L; Olsson P; Pontén J; Carlsson J
    Bioconjug Chem; 1996; 7(5):584-91. PubMed ID: 8889021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors.
    Yang W; Barth RF; Adams DM; Soloway AH
    Cancer Res; 1997 Oct; 57(19):4333-9. PubMed ID: 9331095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression.
    Olsson P; Gedda L; Goike H; Liu L; Collins VP; Pontén J; Carlsson J
    Anticancer Drug Des; 1998 Jun; 13(4):279-89. PubMed ID: 9627668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors.
    Capala J; Barth RF; Bendayan M; Lauzon M; Adams DM; Soloway AH; Fenstermaker RA; Carlsson J
    Bioconjug Chem; 1996; 7(1):7-15. PubMed ID: 8741985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
    Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
    Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF-receptor targeted liposomes with boronated acridine: growth inhibition of cultured glioma cells after neutron irradiation.
    Kullberg EB; Wei Q; Capala J; Giusti V; Malmström PU; Gedda L
    Int J Radiat Biol; 2005 Aug; 81(8):621-9. PubMed ID: 16298943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.
    Yang W; Barth RF; Wu G; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Binns PJ; Riley K; Patel H; Coderre JA; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):981-5. PubMed ID: 15308179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran.
    Sundberg AL; Blomquist E; Carlsson J; Steffen AC; Gedda L
    Nucl Med Biol; 2003 Apr; 30(3):303-15. PubMed ID: 12745022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
    Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
    Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of an end-end coupled mEGF-dextran conjugate using a cultured human glioma cell line.
    Zhao Q; Carlsson J
    Int J Oncol; 1997 Dec; 11(6):1263-9. PubMed ID: 21528333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent.
    Sundberg AL; Orlova A; Bruskin A; Gedda L; Carlsson J; Blomquist E; Lundqvist H; Tolmachev V
    Cancer Biother Radiopharm; 2003 Aug; 18(4):643-54. PubMed ID: 14503960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
    Deguchi Y; Kurihara A; Pardridge WM
    Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introductory experiments on ligand liposomes as delivery agents for boron neutron capture therapy.
    Bohl Kullberg E; Carlsson J; Edwards K; Capala J; Sjöberg S; Gedda L
    Int J Oncol; 2003 Aug; 23(2):461-7. PubMed ID: 12851696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
    Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
    Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy.
    Shukla S; Wu G; Chatterjee M; Yang W; Sekido M; Diop LA; Müller R; Sudimack JJ; Lee RJ; Barth RF; Tjarks W
    Bioconjug Chem; 2003; 14(1):158-67. PubMed ID: 12526705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
    Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
    Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor.
    Cristiano RJ; Roth JA
    Cancer Gene Ther; 1996; 3(1):4-10. PubMed ID: 8785711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.